Correction: Proteomics-identified bvg-activated autotransporters protect against bordetella pertussis in a mouse model (PLoS ONE (2014) 9:8 (e105011) DOI: 10.1371/journal.pone.0105011);Proteomics-identified Bvg-activated autotransporters protect against Bordetella pertussis in a mouse model

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  De Gouw, Daan ^a   De Jonge, Marien I ^a   Hermans, Peter W M ^a,d   Wessels, Hans J C T ^a   Zomer, Aldert ^a   Berends, Alinda ^a   Pratt, Catherine ^c   Berbers, Guy A ^b   Mooi, Frits R ^a,b   Diavatopoulos, Dimitri A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BVG ACTIVATED PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; PERTUSSIS VACCINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; FEMALE; FHAB GENE; FIM3 GENE; GENE EXPRESSION; IN VITRO STUDY; KPST GENE; LUNG PARENCHYMA; MOUSE; NASOPHARYNX; NONHUMAN; OMPA GENE; OMPP GENE; PERTUSSIS; PRN GENE; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEOMICS; PTXA GENE; REGULATOR GENE; SPHB1 GENE; VAG8 GENE; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; IMMUNOLOGY; LUNG; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; WHOOPING COUGH;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BORDETELLA PERTUSSIS; DISEASE MODELS, ANIMAL; FEMALE; LUNG; MICE; MICE, INBRED BALB C; PERTUSSIS VACCINE; PROTEOMICS; WHOOPING COUGH;

EID: 84910667031     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113322     Document Type: Erratum

References (55)

1. Boulton J (2013) The UK pertussis epidemic: implications for immunisation. Br J Nurs 22: 1046-1050.
2. Campbell P, McIntyre P, Quinn H, Hueston L, Gilbert GL, et al. (2012) Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS One 7: e35874.
3. van der Maas NA, Mooi FR, de Greeff SC, Berbers GA, Spaendonck MA, et al. (2013) Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? Vaccine 31: 4541-4547.
4. Witt MA, Katz PH, Witt DJ (2012) Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 54: 1730-1735.
5. Bisgard KM, Pascual FB, Ehresmann KR, Miller CA, Cianfrini C, et al. (2004) Infant pertussis: who was the source? Pediatr Infect Dis J 23: 985-989. (Pubitemid 40824285)
6. de Greeff SC, Mooi FR, Westerhof A, Verbakel JM, Peeters MF, et al. (2010) Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 50: 1339-1345.
7. Kowalzik F, Barbosa AP, Fernandes VR, Carvalho PR, Avila-Aguero ML, et al. (2007) Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 26: 238-242. (Pubitemid 46340771)
8. Warfel JM, Zimmerman LI, Merkel TJ (2013) Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A.
9. Mooi FR, Van Der Maas NA, De Melker HE (2013) Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect: 1-10.
10. de Gouw D, Hermans PW, Bootsma HJ, Zomer A, Heuvelman K, et al. (2014) Differentially expressed genes in Bordetella pertussis strains belonging to a lineage which recently spread globally. PLoS One 9: e84523.
11. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, et al. (2009) Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 15: 1206-1213.
12. Barkoff AM, Mertsola J, Guillot S, Guiso N, Berbers G, et al. (2012) Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol 19: 1703-1704.
13. Lam C, Octavia S, Ricafort L, Sintchenko V, Gilbert GL, et al. (2014) Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis 20: 626-633.
14. Otsuka N, Han HJ, Toyoizumi-Ajisaka H, Nakamura Y, Arakawa Y, et al. (2012) Prevalence and genetic characterization of pertactin-deficient Bordetella pertussis in Japan. PLoS One 7: e31985.
15. Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison M, et al. (2013) Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the US. Clin Vaccine Immunol.
16. Polewicz M, Gracia A, Garlapati S, van Kessel J, Strom S, et al. (2013) Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies. Vaccine 31: 3148-3155.
17. Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, et al. (2013) Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 9: e1003264.
18. Decker KB, James TD, Stibitz S, Hinton DM (2012) The Bordetella pertussis model of exquisite gene control by the global transcription factor BvgA. Microbiology 158: 1665-1676.
19. de Gouw D, Diavatopoulos DA, Bootsma HJ, Hermans PW, Mooi FR (2011) Pertussis: a matter of immune modulation. FEMS Microbiol Rev 35: 441-474.
20. Melton AR, Weiss AA (1993) Characterization of environmental regulators of Bordetella pertussis. Infect Immun 61: 807-815. (Pubitemid 23059634)
21. Bart MJ, van Gent M, van der Heide HG, Boekhorst J, Hermans P, et al. (2010) Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics 11: 627.
22. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, et al. (2003) Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 35: 32-40. (Pubitemid 37048593)
23. Tsou CC, Tsai CF, Tsui YH, Sudhir PR, Wang YT, et al. (2010) IDEAL-Q, an automated tool for label-free quantitation analysis using an efficient peptide alignment approach and spectral data validation. Mol Cell Proteomics 9: 131-144.
24. Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, et al. (2014) Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio 5: e01074.
25. King AJ, van Gorkom T, Pennings JL, van der Heide HG, He Q, et al. (2008) Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics 9: 311.
26. Yu NY, Wagner JR, Laird MR, Melli G, Rey S, et al. (2010) PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics 26: 1608-1615.
27. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, et al. (2005) Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 4: 1265-1272. (Pubitemid 41448714)
28. Neo Y, Li R, Howe J, Hoo R, Pant A, et al. (2010) Evidence for an intact polysaccharide capsule in Bordetella pertussis. Microbes Infect 12: 238-245.
29. Roberts M, Tite JP, Fairweather NF, Dougan G, Charles IG (1992) Recombinant P.69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection. Vaccine 10: 43-48.
30. Sukumar N, Love CF, Conover MS, Kock ND, Dubey P, et al. (2009) Active and passive immunizations with Bordetella colonization factor A protect mice against respiratory challenge with Bordetella bronchiseptica . Infect Immun 77: 885-895.
31. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, et al. (1988) Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334: 255-258.
32. Nurminen M, Butcher S, Idanpaan-Heikkila I, Wahlstrom E, Muttilainen S, et al. (1992) The class 1 outer membrane protein of Neisseria meningitidis produced in Bacillus subtilis can give rise to protective immunity. Mol Microbiol 6: 2499-2506.
33. Marr N, Shah NR, Lee R, Kim EJ, Fernandez RC (2011) Bordetella pertussis autotransporter Vag8 binds human C1 esterase inhibitor and confers serum resistance. PLoS One 6: e20585.
34. Mazar J, Cotter PA (2006) Topology and maturation of filamentous haemagglutinin suggest a new model for two-partner secretion. Mol Microbiol 62: 641-654. (Pubitemid 44571591)
35. Coutte L, Willery E, Antoine R, Drobecq H, Locht C, et al. (2003) Surface anchoring of bacterial subtilisin important for maturation function. Mol Microbiol 49: 529-539. (Pubitemid 36857087)
36. Mobberley-Schuman PS, Weiss AA (2005) Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils. Infect Immun 73: 7317-7323. (Pubitemid 41587632)
37. Kim JH, Skountzou I, Compans R, Jacob J (2009) Original antigenic sin responses to influenza viruses. J Immunol 183: 3294-3301.
38. de Greeff SC, de Melker HE, van Gageldonk PG, Schellekens JF, van der Klis FR, et al. (2010) Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One 5: e14183.
39. Kirimanjeswara GS, Mann PB, Harvill ET (2003) Role of antibodies in immunity to Bordetella infections. Infect Immun 71: 1719-1724. (Pubitemid 36368699)
40. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, et al. (2005) CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A 102: 4848-4853. (Pubitemid 40471542)
41. Trzcinski K, Thompson CM, Srivastava A, Basset A, Malley R, et al. (2008) Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect Immun 76: 2678-2684.
42. Zhang Z, Clarke TB, Weiser JN (2009) Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 119: 1899-1909.
43. Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, et al. (2008) Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 4: e1000159.
44. Dunne A, Ross PJ, Pospisilova E, Masin J, Meaney A, et al. (2010) Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J Immunol 185: 1711-1719.
45. Fedele G, Spensieri F, Palazzo R, Nasso M, Cheung GY, et al. (2010) Bordetella pertussis commits human dendritic cells to promote a Th1/Th17 response through the activity of adenylate cyclase toxin and MAPK-pathways. PLoS One 5: e8734.
46. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH (2006) TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 177: 7980-7989. (Pubitemid 44846315)
47. Warfel JM, Merkel TJ (2013) Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol 6: 787-796.
48. van Gent M, Bart MJ, van der Heide HG, Heuvelman KJ, Mooi FR (2012) Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One 7: e46407.
49. Thalen M, van den IJ, Jiskoot W, Zomer B, Roholl P, et al. (1999) Rational medium design for Bordetella pertussis: basic metabolism. J Biotechnol 75: 147-159.
50. Cron LE, Stol K, Burghout P, van Selm S, Simonetti ER, et al. (2011) Two DHH subfamily 1 proteins contribute to pneumococcal virulence and confer protection against pneumococcal disease. Infect Immun 79: 3697-3710.
51. Hijnen M, van Gageldonk PG, Berbers GA, van Woerkom T, Mooi FR (2005) The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif 41: 106-112. (Pubitemid 40406369)
52. McConnell MJ, Pachon J (2011) Expression, purification, and refolding of biologically active Acinetobacter baumannii OmpA from Escherichia coli inclusion bodies. Protein Expression and Purification 77: 98-103.
53. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
54. Abdillahi H, Poolman JT (1988) Typing of group-B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA. J Med Microbiol 26: 177-180.
55. Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS (2010) The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun 78: 704-715.